1. Introduction

Counterfeit Vaccine International Liability refers to the legal responsibility of governments, pharmaceutical manufacturers, biotechnology companies, distributors, importers, exporters, healthcare institutions, regulatory authorities and other commercial actors involved in the manufacture, distribution, importation, exportation or administration of counterfeit vaccines across international borders.

Counterfeit vaccines represent a serious threat to international public health because they may contain incorrect ingredients, insufficient active substances, harmful contaminants, false labelling or no genuine pharmaceutical ingredients whatsoever. Their circulation can undermine vaccination programmes, cause physical injury or death, weaken public confidence in healthcare institutions and create international disputes concerning responsibility and compensation.

International liability becomes particularly complicated when the manufacturer operates in one country, the counterfeit product is manufactured in another, the distribution network crosses several jurisdictions and the injured patient receives the vaccine in a different country.

The central legal question is:

Who should bear legal responsibility when a counterfeit vaccine causes injury or death across international borders, and under what principles of international law can that responsibility be established?

There is no single universal treaty that comprehensively governs all counterfeit-vaccine injuries. Liability therefore emerges from the interaction of international criminal cooperation, pharmaceutical regulation, product liability, human rights, trade law, state responsibility and domestic civil and criminal law.

2. Meaning and Nature of Counterfeit Vaccines

A counterfeit vaccine is a product deliberately misrepresented as an authentic, authorised or approved vaccine, particularly concerning its identity, composition, source, manufacturing history or regulatory status.

The World Health Organization uses the terminology substandard and falsified medical products. These categories should be distinguished:

Falsified vaccines: Products that deliberately or fraudulently misrepresent their identity, composition or source.

Substandard vaccines: Authorised products that fail to meet applicable quality standards or specifications.

Unauthorised vaccines: Products distributed without the required regulatory approval, which are not necessarily counterfeit.

Adulterated vaccines: Products whose composition or quality has been unlawfully altered or contaminated.

This distinction is legally important because intentional deception, negligent manufacturing and regulatory non-compliance may produce different forms of liability.

Counterfeit vaccine offences may include:

Manufacturing vaccines under false pharmaceutical identities.

Forging regulatory approval certificates.

Misrepresenting vaccine ingredients or efficacy.

Using counterfeit packaging, labels and batch numbers.

Smuggling falsified vaccines across national borders.

Selling counterfeit vaccines through digital platforms.

Administering fraudulent vaccines to unsuspecting patients.

Concealing adverse effects or falsified manufacturing records.

3. International Legal Framework

A. WHO framework

The World Health Organization (WHO) provides an important international institutional framework for preventing, identifying and responding to falsified medical products.

Its activities include:

International information exchange.

Identification of falsified medical products.

Technical assistance to national regulatory authorities.

Strengthening pharmaceutical supply-chain surveillance.

Supporting national enforcement mechanisms.

Promoting international cooperation against falsified medicines.

The WHO's Member State Mechanism on Substandard and Falsified Medical Products facilitates international cooperation.

However, WHO guidance and institutional mechanisms should not be confused with a universal treaty establishing automatic civil compensation for every counterfeit-vaccine injury.

B. International Covenant on Economic, Social and Cultural Rights, 1966

Article 12 recognises the right to the highest attainable standard of physical and mental health.

States have obligations to:

Protect individuals against dangerous pharmaceutical products.

Maintain effective public-health regulatory systems.

Promote access to safe medicines and vaccines.

Prevent foreseeable threats to public health.

Provide appropriate remedies where rights violations occur.

Article 12 is particularly relevant where government authorities knowingly permit dangerous counterfeit vaccines to circulate or fail to take reasonable regulatory measures.

The Committee on Economic, Social and Cultural Rights elaborated these obligations in General Comment No. 14 (2000).

C. International Health Regulations, 2005

The International Health Regulations (2005) establish international obligations concerning public-health risks and international cooperation.

Their relevance includes:

Detection of public-health threats.

Notification and information-sharing.

National surveillance systems.

International cooperation.

Public-health emergency preparedness.

A counterfeit vaccine incident may become relevant under the IHR where it creates or contributes to an event capable of constituting an international public-health emergency.

However, the IHR do not independently create a comprehensive product-liability compensation regime.

D. TRIPS Agreement

The TRIPS Agreement establishes minimum standards for intellectual-property protection.

Articles 41–61 concern enforcement, civil remedies, provisional measures, border measures and criminal procedures.

Articles 51–60 address border measures against certain counterfeit trademark and pirated copyright goods.

Counterfeit vaccine packaging, trademarks and pharmaceutical branding may therefore attract intellectual-property enforcement.

Nevertheless, trademark infringement and pharmaceutical product liability are separate legal questions. A vaccine can be medically dangerous without infringing a trademark, and trademark infringement does not automatically establish patient injury.

E. United Nations Convention against Transnational Organized Crime, 2000

The UN Convention against Transnational Organized Crime (UNTOC) may become relevant when counterfeit-vaccine operations involve an organised criminal group and satisfy the Convention's applicable requirements.

It facilitates:

International criminal cooperation.

Extradition.

Mutual legal assistance.

Confiscation of criminal proceeds.

Cooperation in investigations.

Measures against organised transnational criminal activity.

It does not automatically classify every counterfeit-vaccine transaction as organised crime.

F. Council of Europe MEDICRIME Convention, 2011

The MEDICRIME Convention is particularly important because it specifically addresses counterfeiting of medical products.

It criminalises, subject to the Convention's requirements:

Manufacturing counterfeit medical products.

Supplying, offering to supply and trafficking in counterfeit products.

Falsifying relevant documents.

Unauthorised manufacturing or supply in specified circumstances.

Aiding and abetting relevant offences.

It also provides for corporate liability, international cooperation, victim protection and investigative coordination.

The Convention is a binding treaty for its parties, rather than a universally applicable global instrument. Its application to a particular vaccine incident depends on the states involved and their treaty obligations.

4. Forms of International Liability

A. Manufacturer Liability

A manufacturer may incur liability when it deliberately produces or participates in producing a counterfeit vaccine.

Potential grounds include:

Fraudulent manufacture.

False pharmaceutical certification.

Negligent quality control.

Deliberate contamination.

Concealment of manufacturing defects.

False representation concerning vaccine safety or efficacy.

Unlawful use of another manufacturer's identity.

Manufacturer liability may arise under criminal law, civil product-liability law, consumer-protection legislation and pharmaceutical regulatory legislation.

An important distinction exists between an authentic manufacturer whose product has been counterfeited by an independent criminal organisation and a manufacturer that knowingly participates in falsification.

The genuine manufacturer should not automatically become liable merely because criminals have copied its branding.

B. Distributor and Importer Liability

Distributors and importers may be responsible when they knowingly or negligently introduce counterfeit vaccines into commercial or healthcare supply chains.

Their potential liability includes:

Failure to verify suppliers.

Ignoring suspicious batch documentation.

Selling vaccines without required authorisation.

Failure to maintain traceability.

Concealing counterfeit-product complaints.

Continuing distribution after receiving a regulatory warning.

The extent of liability depends on statutory duties, knowledge, negligence, contractual obligations and causation.

C. Exporter Liability

An exporter may incur liability where counterfeit vaccines are knowingly manufactured, packaged, documented or dispatched for international distribution.

Cross-border conduct may engage:

Export-control legislation.

Customs laws.

Pharmaceutical regulations.

Fraud and forgery offences.

Criminal conspiracy provisions.

International mutual legal assistance arrangements.

The exporting state may also face scrutiny if its authorities knowingly facilitate unlawful exports or systematically fail to enforce applicable regulatory duties.

D. Government and State Liability

Government liability raises a more complex legal question.

A state may potentially incur responsibility where an internationally wrongful act is attributable to it and breaches an international obligation binding upon that state.

Relevant circumstances include:

Deliberate government participation in counterfeit vaccine distribution.

Official falsification of vaccine certificates.

Knowing facilitation of illegal pharmaceutical exports.

Failure to comply with an applicable international obligation.

Arbitrary or discriminatory denial of an effective remedy.

However, the mere occurrence of counterfeit vaccine trafficking within a country's territory does not automatically establish international state responsibility.

The principles of state responsibility reflected in the International Law Commission's 2001 Articles on Responsibility of States for Internationally Wrongful Acts require attribution and breach of an applicable international obligation.

Private criminal conduct is not automatically attributable to a government.

E. Hospital and Healthcare Provider Liability

Hospitals, vaccination centres and medical practitioners may incur liability where they administer counterfeit vaccines despite circumstances that should reasonably have alerted them to the product's authenticity or safety.

Possible grounds include:

Negligent procurement.

Failure to verify vaccine authenticity.

Failure to maintain cold-chain records.

Improper storage.

Negligent administration.

Failure to inform patients.

Concealment of known risks.

A healthcare provider's responsibility must be assessed separately from the manufacturer's responsibility.

5. International Product Liability and Compensation

International product liability concerns the responsibility of persons or entities that place defective or dangerous products into commercial circulation.

In counterfeit vaccine cases, victims may pursue compensation for:

Physical injury.

Permanent disability.

Medical expenses.

Loss of income.

Rehabilitation expenses.

Psychological injury, where legally recognised.

Wrongful death and dependency losses.

Other legally recoverable consequential losses.

Three major theories are relevant.

Negligence: The claimant must generally establish a duty of care, breach, causation and legally recognised damage.

Strict product liability: Applicable legislation may impose liability without requiring proof of negligence, subject to statutory requirements and defences.

Fraudulent misrepresentation: A person who deliberately misrepresents a vaccine's identity, composition or source may be liable for resulting legally recoverable losses.

Important international product-liability cases

1. Donoghue v Stevenson (1932) AC 562 — United Kingdom

The House of Lords established the modern negligence principle concerning a manufacturer's duty of care towards the ultimate consumer.

The case concerned a contaminated bottled drink.

Its relevance is that a manufacturer may owe a duty to consumers even without a direct contractual relationship.

Applied to counterfeit vaccines, it provides a foundational framework for evaluating manufacturer negligence, although it does not itself establish liability for an independent counterfeiter.

2. Grant v Australian Knitting Mills Ltd (1936) AC 85 — Privy Council

The case concerned defective clothing that caused dermatitis.

It developed the application of the manufacturer's duty of care to products intended for consumer use.

Its significance lies in establishing that manufacturers may be responsible for defective products reaching consumers through commercial distribution.

3. A v National Blood Authority [2001] 3 All ER 289 — United Kingdom

This is particularly relevant to pharmaceutical and biological product liability.

The English High Court considered liability arising from hepatitis C-contaminated blood products supplied through the national blood service.

The case examined the meaning of a product defect under the Consumer Protection Act 1987.

Its relevance to counterfeit vaccines concerns the protection of patients against dangerous biological products and the legal standards governing product safety.

However, contaminated authentic blood products and deliberately falsified vaccines are legally distinct categories.

4. Bruesewitz v Wyeth LLC, 562 U.S. 223 (2011) — United States

The US Supreme Court considered the scope of vaccine-related design-defect claims under the National Childhood Vaccine Injury Act 1986.

The judgment addressed statutory pre-emption of certain design-defect claims concerning vaccines.

Its relevance is that vaccine injury compensation may be governed by special statutory frameworks rather than ordinary product-liability principles alone.

Importantly, this decision does not provide blanket immunity for counterfeit vaccine manufacturers or distributors.

5. Wyeth v Levine, 555 U.S. 555 (2009) — United States

The Supreme Court examined the relationship between federal pharmaceutical regulation and state failure-to-warn claims.

The judgment recognised that federal drug regulation does not necessarily eliminate all state-law remedies.

Its relevance lies in the interaction between regulatory approval, pharmaceutical warnings and civil liability.

It should not be interpreted as a direct ruling on counterfeit vaccine liability.

6. International Criminal Liability

Counterfeit vaccine trafficking may involve several distinct criminal offences.

The MEDICRIME Convention is particularly relevant to criminalisation and cooperation.

The UN Convention against Transnational Organized Crime may also apply where its organised-crime and other jurisdictional requirements are satisfied.

International cooperation may involve extradition, evidence-sharing, asset recovery, joint investigations and mutual legal assistance.

7. Indian Legal Framework for Counterfeit Vaccine Liability

India has an important domestic legal framework for prosecuting counterfeit pharmaceutical products and compensating victims.

A. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940 is the principal legislation governing the manufacture, import, sale and distribution of drugs, including vaccines.

Important provisions include:

Section 17B – Spurious drugs

A drug may be deemed spurious where, among other circumstances:

It is manufactured under another drug's name.

It imitates or substitutes another drug deceptively.

It carries the name of a fictitious manufacturer.

It has been wholly or partly substituted by another substance.

It falsely purports to be the product of a genuine manufacturer.

This provision is particularly relevant to counterfeit vaccines sold under the identity of internationally recognised pharmaceutical manufacturers.

IndiaCode

Section 18 – Prohibition of manufacture and sale

This provision prohibits specified activities involving drugs that do not comply with statutory requirements, including the manufacture and sale of spurious and adulterated drugs.

Section 18A – Disclosure of manufacturer

It establishes disclosure obligations concerning the identity of manufacturers in the circumstances covered by the provision.

Section 18B – Maintenance of records

It requires prescribed records and information to be maintained and furnished.

Section 27 – Penalties

This provision establishes criminal penalties for specified violations, including offences involving spurious and adulterated drugs.

Section 36AC – Certain offences to be cognizable and non-bailable

This provision provides a special procedural framework for specified serious offences under the Act.

B. Consumer Protection Act, 2019

The Consumer Protection Act, 2019 provides an important route for compensation.

Chapter VI, particularly Sections 82–87, deals with product liability.

Potentially responsible parties include:

Product manufacturers.

Product sellers.

Product service providers.

A claimant may establish liability under the applicable statutory grounds, including manufacturing defects, defective design, deviation from manufacturing specifications, failure to conform to express warranties or inadequate warnings.

A person who manufactures counterfeit vaccines may face substantial liability where the statutory requirements are satisfied.

The Act also requires careful examination of the seller's and service provider's respective statutory grounds of liability.

C. Bharatiya Nyaya Sanhita, 2023

The Bharatiya Nyaya Sanhita, 2023 may apply to associated criminal conduct, including:

Cheating.

Forgery.

Use of forged documents.

Criminal conspiracy.

Criminal breach of trust, where its elements are established.

Other offences connected with fraudulent pharmaceutical transactions.

The exact offences depend on the conduct, evidence and applicable statutory provisions.

D. Constitutional Protection

The Constitution of India provides additional legal protection.

Article 21 – Right to Life

The right to life includes protection of human dignity and health-related interests.

Article 14 – Equality before Law

Government authorities must act fairly and non-arbitrarily in regulatory enforcement and public-health administration.

Article 32 and Article 226

These provisions permit constitutional remedies before the Supreme Court and High Courts respectively, subject to their jurisdictional requirements.

Where public authorities have unlawfully facilitated dangerous vaccine distribution or violated constitutional obligations, appropriate writ remedies may be available.

8. Important Indian Judicial Decisions

The following decisions are relevant to the legal principles governing counterfeit vaccine liability. They are not direct judgments establishing a universal cause of action for counterfeit vaccines.

1. Indian Medical Association v. V.P. Shantha (1995) 6 SCC 651

The Supreme Court examined the applicability of consumer-protection legislation to medical services.

The judgment established important principles concerning the relationship between medical practitioners, hospitals and consumers.

Relevance: Where a hospital or vaccination centre negligently procures or administers counterfeit vaccines, consumer-protection principles may become relevant, depending on the facts and applicable statutory provisions.

Indian Kanoon

2. Spring Meadows Hospital v. Harjol Ahluwalia (1998) 4 SCC 39

The Supreme Court considered medical negligence involving serious injury to a child.

The Court recognised the importance of accountability for negligent medical services and addressed compensation under consumer law.

Relevance: If negligent vaccine administration causes injury, this decision provides an important foundation for examining healthcare-provider liability.

3. M.C. Mehta v. Union of India (1987) 1 SCC 395 — Oleum Gas Leak Case

The Supreme Court developed the principle of absolute liability for enterprises engaged in hazardous or inherently dangerous activities.

The principle is significant in Indian environmental and industrial liability jurisprudence.

Relevance: It may inform arguments about responsibility for hazardous industrial activities, but it should not automatically be applied to every pharmaceutical manufacturer or counterfeit-vaccine incident.

4. Jacob Mathew v. State of Punjab (2005) 6 SCC 1

The Supreme Court examined the standards governing criminal liability for medical negligence.

The judgment distinguished ordinary negligence from the higher degree of negligence required for criminal prosecution of medical professionals.

Relevance: A healthcare professional who administers a counterfeit vaccine should not automatically face criminal negligence liability merely because the vaccine causes harm. The applicable offence and the necessary mental or negligence elements must be established.

5. Bhupendra Kumar v. State of Rajasthan (2023)

This matter involved allegations relating to serious drug-regulatory violations and counterfeit or spurious drugs.

The Supreme Court's bail-related consideration is relevant to the procedural treatment of serious pharmaceutical offences.

It should not be treated as a definitive ruling on international counterfeit-vaccine compensation or the substantive liability of manufacturers.

IndiaCode

9. International Jurisdiction and Cross-Border Responsibility

One of the most difficult aspects of counterfeit vaccine litigation is determining which country has jurisdiction.

Consider the following hypothetical situation:

Vaccine counterfeiting takes place in Country A.

Packaging and certification fraud occur in Country B.

The product is exported through Country C.

A distributor sells it in Country D.

A patient suffers injury in Country E.

Several jurisdictions may have legitimate legal interests.

A. Territorial Jurisdiction

A country may prosecute offences committed within its territory.

For example, the country where counterfeit vaccines are manufactured may prosecute the manufacturers under its criminal law.

B. Nationality Jurisdiction

A country may exercise jurisdiction over certain offences committed abroad by its nationals, where its domestic law permits.

C. Effects-Based Jurisdiction

A state may have a legitimate basis for regulating conduct outside its territory where the conduct produces substantial effects within its jurisdiction, subject to applicable international law.

D. Civil Jurisdiction

The injured patient may seek compensation in a country with an appropriate jurisdictional connection.

Relevant considerations include:

The defendant's domicile.

The place of manufacture.

The place of distribution.

The place of injury.

Applicable jurisdictional legislation.

Contractual jurisdiction clauses.

Rules governing recognition and enforcement of foreign judgments.

E. Extradition and Mutual Legal Assistance

International criminal investigations may require:

Identification of foreign suspects.

Collection of manufacturing records.

Examination of pharmaceutical samples.

Exchange of forensic reports.

Bank-account investigations.

Freezing and confiscation of criminal proceeds.

Extradition, where legally permissible.

The MEDICRIME Convention expressly promotes cooperation between health, police and customs authorities. Its Articles 17 and following are particularly relevant to information exchange and cooperation.

The MEDICRIME Convention+1

10. Liability of Multinational Pharmaceutical Corporations

Multinational pharmaceutical corporations may face complex liability questions when counterfeit vaccines imitate their genuine products.

Three situations must be distinguished.

Situation 1: Independent counterfeiting

An unrelated criminal organisation manufactures counterfeit vaccines using a genuine company's brand.

The counterfeiter is the primary potential wrongdoer. The genuine company is not automatically liable for the criminal's independent conduct.

Situation 2: Negligent supply-chain control

A genuine manufacturer or authorised distributor negligently allows counterfeit products to enter its controlled supply chain.

Liability may arise if an applicable legal duty, breach, causation and damage are established.

Situation 3: Corporate participation

Corporate officers knowingly participate in the production, certification or distribution of falsified vaccines.

The corporation and responsible individuals may face civil, administrative or criminal liability, depending on applicable national law.

Corporate liability is expressly addressed by Article 11 of the MEDICRIME Convention for its parties.

lagen.nu

11. Human Rights Liability and Victim Protection

Counterfeit vaccines may implicate internationally protected human rights.

A. Right to Life

Article 6 of the International Covenant on Civil and Political Rights protects the right to life.

Where state authorities knowingly facilitate the circulation of life-threatening counterfeit vaccines, questions of state responsibility and violations of the right to life may arise.

B. Right to Health

Article 12 of the International Covenant on Economic, Social and Cultural Rights requires states to take appropriate measures to protect public health.

Regulatory supervision, pharmaceutical safety and access to reliable healthcare are important components of this obligation.

C. Right to an Effective Remedy

Victims should have access to appropriate domestic legal remedies, including:

Criminal investigation.

Civil compensation proceedings.

Consumer-protection mechanisms.

Medical rehabilitation.

Appropriate information concerning the falsified product.

Access to evidence necessary to establish injury and causation.

D. Protection of Vulnerable Groups

Special consideration may be required where counterfeit vaccines affect children, pregnant women, elderly persons, immunocompromised individuals or communities dependent on publicly funded vaccination programmes.

The nature and extent of legal protection depend on the relevant domestic and international obligations.

12. Evidentiary Requirements in International Counterfeit Vaccine Litigation

Establishing liability requires scientific, documentary and commercial evidence.

The following evidence may be essential:

A. Causation

A claimant must establish the necessary causal connection between the counterfeit vaccine and the injury under the applicable legal standard.

This can be complicated because:

The patient may have pre-existing medical conditions.

The counterfeit product may contain unknown ingredients.

The injury may have multiple causes.

Laboratory samples may be unavailable.

The distribution chain may involve multiple intermediaries.

Scientific evidence and expert testimony are therefore particularly important.

B. Chain of Custody

The authenticity and integrity of vaccine samples must be preserved.

Investigators should document:

The location of seizure.

The identity of the investigating officer.

The batch and packaging details.

The method of collection.

Storage conditions.

Laboratory transfer records.

Testing methodology.

Final forensic findings.

Failure to preserve evidence may undermine criminal prosecution and civil compensation claims.

13. Relevant International Examples of Counterfeit Vaccine Incidents

Actual WHO alerts demonstrate the international character of this problem.

A. Falsified AstraZeneca COVID-19 vaccine, Iran (2021)

On 4 November 2021, WHO issued Medical Product Alert No. 7/2021 concerning falsified AstraZeneca COVID-19 vaccine identified in Iran.

The products consisted of illicitly refilled vials of used and discarded genuine vaccine containers.

The incident illustrates the legal distinction between genuine pharmaceutical packaging and authentic pharmaceutical contents.

It also demonstrates the importance of supply-chain authentication and product traceability.

World Health Organization

B. Falsified Dukoral oral cholera vaccine, Bangladesh (2019)

On 21 March 2019, WHO issued Medical Product Alert No. 4/2019 concerning falsified Dukoral oral cholera vaccines circulating in Bangladesh.

Approximately 8,000 falsified packs had reportedly been distributed.

The incident demonstrates the importance of cooperation between manufacturers, national health authorities and international public-health institutions.

World Health Organization

These incidents are important factual examples, but the WHO alerts themselves are not judicial determinations of civil or criminal liability.

14. Structural Problems in International Counterfeit Vaccine Liability

Several structural weaknesses complicate international enforcement.

1. Absence of universal harmonisation

Different countries define pharmaceutical counterfeiting, corporate criminal liability and product defects differently.

2. Fragmented jurisdiction

Manufacturing, exportation, distribution and injury may occur in different countries.

3. Corporate complexity

Multinational corporate structures can make it difficult to identify the responsible legal entity.

4. Compensation difficulties

Victims may face difficulties obtaining compensation where the counterfeiter is unidentified, insolvent or located abroad.

5. Evidentiary barriers

Laboratory evidence, manufacturing records and financial documents may be located in different jurisdictions.

6. Regulatory weaknesses

Inadequate pharmaceutical inspection, weak customs enforcement and poor traceability facilitate counterfeit distribution.

7. Digital pharmaceutical trafficking

Unregulated online marketplaces and fraudulent websites make identification of sellers and distributors more difficult.

INTERPOL's Operation Pangea demonstrates the importance of international enforcement cooperation. Its seventeenth operation, conducted from December 2024 to May 2025 across 90 countries, resulted in the seizure of approximately 50 million doses of illicit pharmaceuticals.

Interpol

15. Important Legal Principles Emerging from the Case Law

The following cases provide a useful comparative jurisprudential foundation:

Important jurisprudential qualification: There is no established universal judicial doctrine under which every counterfeit-vaccine injury automatically creates international liability for the genuine manufacturer, exporting state or WHO. The above decisions establish related principles that must be applied according to the facts and the governing jurisdiction.

16. Recommendations for Strengthening International Legal Governance

An effective international counterfeit-vaccine liability framework should incorporate the following reforms:

1. International pharmaceutical traceability: Establish interoperable systems for identifying every vaccine batch from manufacturing to administration.

2. Cross-border corporate accountability: Strengthen rules identifying corporate officers and entities responsible for deliberate pharmaceutical falsification.

3. International compensation mechanisms: Explore compensation arrangements for victims where cross-border criminal networks make ordinary recovery impracticable.

4. Mandatory regulatory information exchange: Strengthen rapid notification between national pharmaceutical regulators.

5. Harmonised criminalisation: Encourage states to adopt consistent offences concerning falsified vaccine manufacturing, trafficking and fraudulent certification.

6. International forensic cooperation: Establish recognised standards for vaccine authentication and laboratory evidence.

7. Digital supply-chain regulation: Improve oversight of online pharmaceutical sales and international payment networks.

8. Victim-centred enforcement: Ensure that criminal investigations do not displace the separate rights of injured patients to seek compensation.

9. Public-private accountability: Encourage cooperation among pharmaceutical manufacturers, customs authorities, hospitals and international enforcement institutions.

10. State regulatory accountability: Develop clearer standards for evaluating serious governmental failures to prevent foreseeable pharmaceutical threats.

17. Conclusion

Counterfeit Vaccine International Liability represents an intersection of international criminal law, pharmaceutical regulation, product liability, consumer protection, corporate accountability and human rights.

Its central difficulty is the fragmentation of responsibility across international supply chains.

A counterfeit vaccine may be manufactured by a criminal organisation, packaged in another jurisdiction, exported through international commercial networks and administered to a patient thousands of kilometres away. Establishing liability therefore requires identifying the responsible actors, determining the applicable jurisdiction, proving the necessary causal connection and securing an effective remedy.

The MEDICRIME Convention provides an important treaty-based criminal-law framework, while WHO mechanisms facilitate international public-health cooperation. Domestic product-liability laws and human-rights obligations provide additional avenues for accountability.

For India, the Drugs and Cosmetics Act, 1940, the Consumer Protection Act, 2019, the Bharatiya Nyaya Sanhita, 2023, and constitutional remedies provide important legal mechanisms.

Ultimately, international counterfeit vaccine liability should develop around three foundational principles:

Public-health accountability: No person or organisation should knowingly endanger patients through pharmaceutical falsification.

Corporate and governmental responsibility: Every legally responsible actor should be accountable for its own unlawful conduct or breach of duty.

Victim-centred compensation: Patients suffering injury should have meaningful access to investigation, justice and appropriate compensation.

The broader objective is to establish an international pharmaceutical governance system in which vaccine authenticity, patient safety, corporate responsibility and access to justice are treated as interconnected legal obligations.

18. Selected Primary Legal and Institutional Sources

WHO – Definitions of Substandard and Falsified Medical Products.

WHO – Member State Mechanism.

Council of Europe – MEDICRIME Convention.

United Nations Treaty Collection – MEDICRIME Convention.

UNODC – Falsified Medical Products.

INTERPOL – Pharmaceutical Crime Operations.

India – Drugs and Cosmetics Act, Section 17B.

Indian Medical Association v. V.P. Shantha (1995).

Academic research proposition: Counterfeit Vaccine International Liability can be developed as an independent research area under the broader doctrine of Transnational Pharmaceutical Accountability, examining the relationship between cross-border pharmaceutical fraud, multinational corporate liability, state regulatory responsibility and international victim compensation.